InSite, CIBA Vision Ophthalmics deal

INSV regained from CIBA the U.S. marketing rights to PilaSite, a candidate for glaucoma. In exchange, CIBA received royalty-bearing co-exclusive marketing rights to INSV's ToPreSite product for ocular inflammation/infection, and co-exclusive U.S. marketing rights to INSV's ISV-205 for non-glaucoma-related indications.

INSV said the agreement was part of its strategy to focus solely on glaucoma. The company has completed Phase III trials of PilaSite, but did estimate when it might file an NDA. ...